Tozadenant - Acorda Therapeutics

Drug Profile

Tozadenant - Acorda Therapeutics

Alternative Names: A2a-(3); RO4494351; RO4494351-000; RO4494351-002; SYN-115

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Acorda Therapeutics
  • Class Amides; Antiparkinsonians; Benzothiazoles; Carboxylic acids; Morpholines; Piperidines; Small molecules
  • Mechanism of Action Adenosine A2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Liver disorders; Parkinson's disease

Most Recent Events

  • 20 Nov 2017 Biotie Therapies terminates a phase I trial in Liver disorders (In volunteers) in USA based on previously disclosed agranulocytosis and associated serious adverse events (PO) (NCT03212313)
  • 20 Nov 2017 Biotie Therapies terminates the phase III TOZ-PD trial in Parkinson's disease (Adjunctive treatment) in USA, Canada, Spain, Germany, Czech Republic due to previously disclosed agranulocytosis, associated serious adverse events and safety concerns (PO) (NCT02453386)
  • 20 Nov 2017 Biotie Therapies terminates a phase I trial in Healthy volunteers in Canada based on previously disclosed agranulocytosis, associated serious adverse events and safety concerns (PO) (NCT03200080)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top